Agios Pharmaceuticals Inc’s recently made public that its Director Foster-Cheek Kaye I unloaded Company’s shares for reported $40632.0 on Mar 07 ’24. In the deal valued at $31.62 per share,1,285 shares were sold. As a result of this transaction, Foster-Cheek Kaye I now holds 5,524 shares worth roughly $0.16 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Foster-Cheek Kaye I sold 4,415 shares, generating $141,236 in total proceeds. Upon selling the shares at $31.99, the Director now owns 6,809 shares.
Before that, Goff Brian sold 4,156 shares. Agios Pharmaceuticals Inc shares valued at $135,361 were divested by the Chief Executive Officer at a price of $32.57 per share. As a result of the transaction, Goff Brian now holds 53,780 shares, worth roughly $1.56 million.
Cantor Fitzgerald initiated its Agios Pharmaceuticals Inc [AGIO] rating to an Overweight in a research note published recently. A number of analysts have revised their coverage, including Piper Sandler’s analysts, who began to cover the stock in early February with a ‘”an Overweight”‘ rating. Goldman also remained covering AGIO and has increased its forecast on November 17, 2022 with a “Neutral” recommendation from previously “Sell” rating. SVB Leerink revised its rating on July 27, 2022. It rated AGIO as “an Outperform” which previously was an “a Mkt perform”.
Price Performance Review of AGIO
On Tuesday, Agios Pharmaceuticals Inc [NASDAQ:AGIO] saw its stock fall -2.09% to $29.06. Over the last five days, the stock has lost -3.42%. Agios Pharmaceuticals Inc shares have risen nearly 30.49% since the year began. Nevertheless, the stocks have risen 33.67% over the past one year. While a 52-week high of $35.50 was reached on 02/27/24, a 52-week low of $19.80 was recorded on 01/19/24. SMA at 50 days reached $27.29, while 200 days put it at $25.28. A total of 0.55 million shares were traded, compared to the trading of 0.44 million shares in the previous session.
Levels Of Support And Resistance For AGIO Stock
The 24-hour chart illustrates a support level at 28.54, which if violated will result in even more drops to 28.03. On the upside, there is a resistance level at 29.90. A further resistance level may holdings at 30.75. The Relative Strength Index (RSI) on the 14-day chart is 46.91, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.58, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 94.90%. Stochastics %K at 17.00% indicates the stock is a buying.
How much short interest is there in Agios Pharmaceuticals Inc?
A steep rise in short interest was recorded in Agios Pharmaceuticals Inc stocks on Feb 29, 2024, dropping by 10000.0 shares to a total of 7.33 million shares. Yahoo Finance data shows the prior-month short interest on Jan 31, 2024 was 7.34 million shares. There was a decline of -0.14%, which implies that there is a negative sentiment for the stock. In spite of short shares comprising just 13.20% of the overall stock float, the days-to-cover ratio (short ratio) fell to 8.16.
The most recent change occurred on December 03, 2021 when BofA Securities began covering the stock and recommended ‘”a Buy”‘ rating along with a $54 price target.
